Use of Intravenous vs. Intramuscular Hepatitis B Immunoglobulin in
Prevention of Relapse of Hepatitis B in Post Liver Transplant Patients
Aftab Ahmed Siddiqui, Rakhshinda Jabeen, Moin Ahmed Ansari, Majid Ali Soomro, SaeedAhmed, Masoud Bakheet Khashoub.
OBJECT: To see the response of HBIg in post liver transplant patients in prevention of hepatitis
B relapse by using two different routes of administration.
STUDY DESIGN: prospective comparative study.
PLACE AND DURATION OF STUDY: Sultan Qaboos University Hospital, Oman. From December
2001 December 2007.
PATIENTS AND METHODS: Total 32 patients who underwent cadavaric liver-transplantation due
to hepatitis B related end-stage liver disease were included in this study. Patients were divided
into two groups by simple random technique. HBIg was administered through intravenous route
to subjects of Group 1, whereas to subjects of Group II it was administered through intramuscular
route. All patients received full recommended dose of HBIg with oral lamirudine for the prevention
of relapse. Subjects were followed up for 30-months to record any event of relapse in
RESULTS: There were 24 (75%) males and 8 (25%) females, with median age of 37 years. Pretreatment
HBV - DNA was detected in 28 (87.5%) and anti-HBS levels were 100 in all patients. None of the study subjects in both groups had relapse of Hepatitis
CONCLUSION: Intramuscular route of administrating HBIg in post liver transplant cases secondary
to hepatitis B was found to be as effective as intra venous route.
Key words: Liver transplantation, Hepatitis B, Hepatitis B immunoglobulin, intravenous, intramuscular,